Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8079626 | 0.98 | ST14 (0.49) | ST14GFERESRRGIDO1HIF1A | |
| SCHEMBL23116506 | 0.89 | MAOB (0.47) | ST14GFERESRRGHIF1ACYP3A4 | |
| SCHEMBL23116515 | 0.87 | MAOB (0.50) | ST14GFERHIF1ACYP3A4NOS1 | |
| SCHEMBL12401907 | 0.86 | ST14 (0.51) | ST14IDO1HIF1ACYP3A4NOS1 | |
| SCHEMBL23116505 | 0.85 | MAOB (0.48) | ST14GFERHIF1ACYP3A4NOS1 | |
| SCHEMBL1286912 | 0.84 | KDM4E (0.56) | ST14GFERESRRGIDO1NPC1 | |
| SCHEMBL6682640 | 0.84 | ST14 (0.50) | ST14IDO1HIF1ACYP3A4NOS1 | |
| SCHEMBL6986416 | 0.83 | ST14 (0.50) | ST14GFERESRRGIDO1HIF1A | |
| SCHEMBL18401315 | 0.82 | ST14 (0.49) | ST14IDO1HIF1ACYP3A4NOS1 | |
| SCHEMBL10310202 | 0.82 | NPC1 (0.51) | ST14IDO1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144597-A1 | CHROMATOGRAPHY RESIN HAVING AN ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE LIGAND | BIO-RAD LABORATORIES, INC. | 2025-05-08 | — | — | US | claimed |
| US-11666888-B2 | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand | BIO-RAD LABORATORIES, INC. (US) | 2023-06-06 | — | — | US | claimed |
| EP-0932618-B1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ASTRAZENECA AB (SE) | 2003-12-10 | — | — | EP | claimed |
| EP-0946589-B1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | claimed |
| CN-1116305-C | Peptide derivatives | ZENECA LTD (GB) | 2003-07-30 | — | — | CN | claimed |
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | claimed |
| US-6355617-B1 | PEPTIDES, HYDROPHOBIC RESIDUES, AMINO ACIDS AND SEQUENCE | SYNGENTA LIMITED (GB) | 2002-03-12 | — | — | US | claimed |
| US-6207644-B1 | FOR USE IN TREATING MHC CLASS II DEPENDENT T-CELL MEDIATED AUTOIMMUNE OR INFLAMMATORY DISEASES, SUCH AS RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-03-27 | — | — | US | claimed |
| US-6184207-B1 | A PEPTIDE INCLUDING SPECIFIED PIPERIDINE-CONTAINING GROUP, HAVING AN N-TERMINAL HYDROPHOBIC RESIDUE AND OPTIONALLY AN AMIDATED C-TERMINAL OF SPECIFIED END GROUPS; TREATING MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | claimed |
| EP-0882066-B1 | PEPTIDE DERIVATIVES | ZENECA LTD (GB) | 2000-09-06 | — | — | EP | claimed |
| US-6087336-A | ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | claimed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | claimed |
| EP-0946596-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | claimed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | claimed |
| CN-1213379-A | Peptide derivatives | ZENECA LTD (GB) | 1999-04-07 | — | — | CN | claimed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | claimed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | claimed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | claimed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144597-A1 | CHROMATOGRAPHY RESIN HAVING AN ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE LIGAND | MSR1, RXRA, MLX | ST14 3448/4885GFER 2492/4885ESRRG 73/4885 |
| US-11666888-B2 | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand | MSR1, RXRA, MLX | ST14 3448/4885GFER 2492/4885ESRRG 73/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | ST14 2297/4885GFER 4496/4885ESRRG 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.